Skip to content

Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance

Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01052025
Enrollment
200
Registered
2010-01-20
Start date
2009-08-31
Completion date
2010-04-30
Last updated
2010-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk, Insulin Resistance, Pre-diabetes, Type 2 Diabetes

Brief summary

The incidence rate of type 2 diabetes in Thai populations is high and increasing every year. Cardiovascular disease is the main complication of this disease, which has been defined as an important cause of death among Diabetic patients. This disease is now becoming a major health problem and causes a great economic loss to the country. Evidence shows that Curcumin, Thai herbal medicine, has the effectiveness of prevention and delay of type 2 diabetes. However, there is no scientific study that aims to prove the efficacy of this herb particularly for prevention and delay the disease in Patients with impaired glucose tolerance (pre-diabetes) and insulin resistance.

Interventions

DRUGCurcumin

curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months

Sponsors

Ministry of Health, Thailand
CollaboratorOTHER_GOV
Srinakharinwirot University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients aged 35 years or older with an abnormal fasting plasma glucose (100-125 mg/dl) or with insulin resistance (140-199 mg/dl) by using 75 mg of glucose OGTT.

Exclusion criteria

* Have been diagnosed with diabetes by the results of FPG \>/=126 mg/dl * Present with secondary peripheral arterial disease (PAD) * Present with cardiovascular diseases such as coronary arterial disease and cerebrovascular disease * Receive anticoagulant drugs that have an effect on the measurement of pulse wave velocity (PWV) * Receive antihypertensive or lipid-lowering drugs (ARB, ACEI, fenofibrate, atorvastatin, rosuvastatin, fluvastatin) that have an effect on the measurement of C-reactive protein (CRP) * Present with kidney failure (serum creatinine \> 2.0 mg/dl) or in the process of renal dialysis * Present with hepatitis (ALT level \>/= 3 times the upper limit) * Receive any herbal medications or curcumin * Present with high blood sugar from other causes apart from type 2 diabetes such as receiving steroid drugs, cancer or pancreatic cyst * Present with infection or inflammation that have effect on the level of CRP * Pregnancy or breastfeeding * Have a history of gall bladder diseases or removal

Design outcomes

Primary

MeasureTime frame
To examine the efficacy of curcumin on the delay of degenerative beta-cells in pancrease for protection of Type 2 Diabetes in patients with impaired glucose tolerance (Pre-diabetes)12 months

Secondary

MeasureTime frame
To examine the efficacy of curcumin on the reduction of blood sugar level, lipid profile, insulin resistance status and oxidative stress status in Pre-diabetes patients12 months

Countries

Thailand

Contacts

Primary ContactSomlak Chuengsamarn, Medical Doctor
somlukc@swu.ac.th+663739-5085

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026